The prenatal and newborn genetic testing market size in 2021 stood at US$ 5.72 billion and is projected to reach US$ 21.44 billion by 2031. The market is expected to register a CAGR of 14.5% in 2023–2031. Digital microfluidics for newborn screening is likely to remain key prenatal and newborn genetic testing market trends.
Developing technology capabilities, rising acceptance and awareness of genetic testing for prenatal and neonatal screening, and an increased emphasis on individualized healthcare are some factors that are expanding the market growth. The future of the market is shaped by the crucial role that genetic testing solutions play in improving early diagnosis, well-informed decision-making, and better healthcare outcomes for both pregnant women and babies. Increasing numbers of diagnostic companies operating in the prenatal and newborn screening domain, along with rising public and private investments, are anticipated to augment the market's expansion during the forecast period.
Prenatal genetic testing is performed during pregnancy to diagnose diseases or detect specific genetic abnormalities before 8 to 10 weeks of gestation. Most prenatal genetic tests use a blood sample from the mother for the conduction of various screens. Growing demand for prenatal & newborn genetic testing for identifying genetic abnormalities, as well as the presence of public and private-public organizations such as Genomic Health Inc. and the National Human Genome Research Institute, is supporting the growth of the market. The American Association for Clinical Chemistry (AACC) recognizes newborn screening as a critical factor for improving children’s health. As an effort toward the management of genetic diseases in infants, the AACC endorses public-private efforts to maintain, improve, and expand newborn screening programs. In addition, the increase in maternal age, leading to pregnancy complications, is fueling the demand for prenatal genetic testing globally.
The fetuses in the womb are impacted by various genetic diseases. The way in which these genetic diseases are inherited helps to determine the risk that they pose on pregnancy and the risk of its recurrence. The risk of having genetic diseases in newborn is high in several cases, such as when the parents have another child with a genetic disease, a family history of a genetic disorder, or if either of a parent has a chromosomal abnormality. There is a substantial prevalence of genetic diseases among infants, and these diseases are also responsible for infant mortality globally. Down syndrome is the most common form of intellectual disability in the world. It remains the most common chromosomal condition diagnosed in the US, affecting about 1 in every 700 babies. According to the Centers for Disease Control and Prevention (CDC) data, ~6,000 babies born annually in the US have Down syndrome. The World Health Organization estimates that 240,000 newborns worldwide succumb to death yearly within 28 days of birth due to these diseases. An additional 170,000 children die between the ages of 1 month and 5 years due to congenital diseases. Thus, the prevalence of genetic diseases among infants increases the demand for prenatal and newborn genetic tests, thereby driving the growth of the market.
With the advancing field of genomic science, genetic and genomic tests are becoming more customary in various clinical and healthcare institutes. Governments and healthcare regulatory bodies across the world are comprehending the importance of genetic tests and the benefits that these tests offer. To ensure the health of newborns, various initiatives are taken by government worldwide that require babies to undergo newborn screening. The California Newborn Screening (NBS) Program is a public health program that screens all newborns for several serious but treatable genetic disorders. Similarly, in India, the Department of Biotechnology launched the UMMID Initiative (The Unique Methods of Management and Treatment of Inherited Disorders) in 2019. It is designed to promote the babies' genetic screening in the nation. Thus, the increase in support from the government to promote the use of prenatal and new genetic tests across the world is expected to contribute to the market's growth in the future.
Key segments that contributed to the derivation of the prenatal and newborn genetic testing market analysis are product, disease indication, and end user.
The geographic scope of the prenatal and newborn genetic testing market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.
North America has dominated the prenatal and newborn genetic testing market. North America market is expanding due to a number of factors, including the increase in the prevalence of genetic diseases among infants, supportive government initiatives as well as initiatives undertaken by various organizations to facilitate the use of prenatal and newborn testing, and increasing birth rate. As per the CDC, birth defects affect one in every 33 babies born annually in the US. Moreover, the demand for the market in the region is anticipated to grow significantly during the forecast period owing to regulatory mandates for performance of prenatal and newborn tests, increasing focus on advanced method integration in healthcare, and the launch of non-invasive tests for diagnosis of prenatal and genetic tests in the region. Asia Pacific is anticipated to grow with the highest CAGR in the coming years.
The regional trends and factors influencing the Prenatal and Newborn Genetic Testing Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Prenatal and Newborn Genetic Testing Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 5.72 Billion |
| Market Size by 2031 | US$ 21.44 Billion |
| Global CAGR (2023 - 2031) | 14.5% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2031 |
| Segments Covered |
By Product
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The Prenatal and Newborn Genetic Testing Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Prenatal and Newborn Genetic Testing Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
The prenatal and newborn genetic testing market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in the market for prenatal and newborn genetic testing and strategies:
The “Prenatal and Newborn Genetic Testing Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas: